At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, discusses topics of his highlight session at the congress that summarised research highlights in the management of patients with ovarian cancer in 2015, including the treatment of relapsed ovarian cancer and optimisation of the use of poly(ADP-ribose) polymerase (PARP) inhibitors.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews